Introduction: This study aimed to compare the effectiveness outcomes of Child-Pugh class A patients with unresectable hepatocellular carcinoma (HCC) treated with first-line atezolizumab-bevacizumab and lenvatinib. Methods: This retrospective study included patients with Child-Pugh A unresectable HCC who were administered first-line treatment with either atezolizumab-bevacizumab (n = 368) or lenvatinib (n = 229) at Asan Medical Center (Seoul, Korea). Effectiveness outcomes were analyzed along with the inverse probability treatment weighting (IPTW) analysis to adjust for potential confounders. Results: Hepatitis B virus infection was the most common cause of HCC. With median follow-up duration of 11.9 for atezolizumab-bevacizumab and 20.9 months for the lenvatinib groups, patients treated with atezolizumab-bevacizumab exhibited superior progression-free survival (PFS) and overall survival (OS) than those treated with lenvatinib (median PFS 6.3 vs. 4.9 months, p = 0.031; and median OS 18.5 vs. 11.3 months, p < 0.001). After IPTW adjustment, atezolizumab-bevacizumab remained associated with favorable OS (median OS of 17.9 vs. 12.3 months, p = 0.010). Treatment with atezolizumab-bevacizumab was an independent factor of OS in both the entire and IPTW-adjusted cohorts. For patients with a viral etiology, the atezolizumab-bevacizumab group exhibited significantly longer OS than the lenvatinib group in both entire and IPTW-adjusted cohorts (p < 0.001 and p = 0.006, respectively). Conversely, both groups showed comparable OS among those with a nonviral etiology (p = 0.656 and p = 0.616, respectively). Conclusions: Atezolizumab-bevacizumab showed superior OS compared to lenvatinib in Asian patients with unresectable HCC.

In our study, we compared two treatments, atezolizumab-bevacizumab and lenvatinib, for unresectable hepatocellular carcinoma in Asian patients. Our findings showed that atezolizumab-bevacizumab provided better overall survival outcomes than lenvatinib, particularly for patients with a viral etiology. This suggests that atezolizumab-bevacizumab could be a more effective treatment option for this type of cancer in Asian patients.

1.
Sung
H
,
Ferlay
J
,
Siegel
RL
,
Laversanne
M
,
Soerjomataram
I
,
Jemal
A
, et al
.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2021
;
71
(
3
):
209
49
.
2.
Kudo
M
,
Finn
RS
,
Qin
S
,
Han
KH
,
Ikeda
K
,
Piscaglia
F
, et al
.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
.
Lancet
.
2018
;
391
(
10126
):
1163
73
.
3.
Finn
RS
,
Qin
S
,
Ikeda
M
,
Galle
PR
,
Ducreux
M
,
Kim
TY
, et al
.
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
.
N Engl J Med
.
2020
;
382
(
20
):
1894
905
.
4.
Abou-Alfa
GK
,
Lau
G
,
Kudo
M
,
Chan
SL
,
Kelley
RK
,
Furuse
J
, et al
.
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
.
NEJM Evid
.
2022
;
1
:
8
.
5.
Qin
S
,
Chan
SL
,
Gu
S
,
Bai
Y
,
Ren
Z
,
Lin
X
, et al
.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
.
Lancet
.
2023
;
402
(
10408
):
1133
46
.
6.
Kim
HD
,
Jung
S
,
Lim
HY
,
Ryoo
BY
,
Ryu
MH
,
Chuah
S
, et al
.
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
.
Nat Med
.
2024
;
30
(
3
):
699
707
.
7.
Singal
AG
,
Llovet
JM
,
Yarchoan
M
,
Mehta
N
,
Heimbach
JK
,
Dawson
LA
, et al
.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
.
Hepatology
.
2023
;
78
(
6
):
1922
65
.
8.
Reig
M
,
Forner
A
,
Rimola
J
,
Ferrer-Fàbrega
J
,
Burrel
M
,
Garcia-Criado
Á
, et al
.
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
.
J Hepatol
.
2022
;
76
(
3
):
681
93
.
9.
Casadei-Gardini
A
,
Scartozzi
M
,
Tada
T
,
Yoo
C
,
Shimose
S
,
Masi
G
, et al
.
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis
.
Liver Int
.
2021
;
41
(
6
):
1389
97
.
10.
Casadei-Gardini
A
,
Rimini
M
,
Tada
T
,
Suda
G
,
Shimose
S
,
Kudo
M
, et al
.
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
.
Eur J Cancer
.
2023
;
180
:
9
20
.
11.
Su
CW
,
Teng
W
,
Lin
PT
,
Jeng
WJ
,
Chen
KA
,
Hsieh
YC
, et al
.
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma
.
Cancer Med
.
2023
;
12
(
6
):
7077
89
.
12.
Kim
BK
,
Cheon
J
,
Kim
H
,
Kang
B
,
Ha
Y
,
Kim
DY
, et al
.
Atezolizumab/bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study
.
Cancers
.
2022
;
14
(
7
):
1747
.
13.
Rimini
M
,
Rimassa
L
,
Ueshima
K
,
Burgio
V
,
Shigeo
S
,
Tada
T
, et al
.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
.
ESMO Open
.
2022
;
7
(
6
):
100591
.
14.
Maesaka
K
,
Sakamori
R
,
Yamada
R
,
Doi
A
,
Tahata
Y
,
Miyazaki
M
, et al
.
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
.
Hepatol Res
.
2022
;
52
(
7
):
630
40
.
15.
Park
JW
,
Chen
M
,
Colombo
M
,
Roberts
LR
,
Schwartz
M
,
Chen
PJ
, et al
.
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
.
Liver Int
.
2015
;
35
(
9
):
2155
66
.
16.
Kim
HD
,
Park
YG
,
Kim
S
,
Kim
KP
,
Park
SR
,
Ryu
MH
, et al
.
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
.
Hepatol Int
.
2024
;
18
(
3
):
973
83
.
17.
McNamara
MG
,
Slagter
AE
,
Nuttall
C
,
Frizziero
M
,
Pihlak
R
,
Lamarca
A
, et al
.
Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis
.
Eur J Cancer
.
2018
;
105
:
1
9
.
18.
Albillos
A
,
Lario
M
,
Álvarez-Mon
M
.
Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance
.
J Hepatol
.
2014
;
61
(
6
):
1385
96
.
19.
Pfister
D
,
Núñez
NG
,
Pinyol
R
,
Govaere
O
,
Pinter
M
,
Szydlowska
M
, et al
.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
.
Nature
.
2021
;
592
(
7854
):
450
6
.
20.
Espinoza
M
,
Muquith
M
,
Lim
M
,
Zhu
H
,
Singal
AG
,
Hsiehchen
D
.
Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150
.
Gastroenterology
.
2023
;
165
(
1
):
286
8.e4
.
21.
Copil
FD
,
Campani
C
,
Lequoy
M
,
Sultanik
P
,
Blaise
L
,
Wagner
M
, et al
.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
.
Liver Int
.
2024
;
44
(
4
):
931
43
.
22.
Meyer
T
,
Galani
S
,
Lopes
A
,
Vogel
A
.
Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease
.
J Hepatol
.
2023
;
79
(
2
):
e73
6
.
You do not currently have access to this content.